CYTOKINETICS, INCORPORATED Payment for Debt Extinguishment or Debt Prepayment Cost
CYTOKINETICS, INCORPORATED (CYTK) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2025-02-27
- CYTOKINETICS, INCORPORATED payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-12-31 was $0.00.
- CYTOKINETICS, INCORPORATED payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-09-30 was $0.00.
- CYTOKINETICS, INCORPORATED payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-06-30 was $0.00.
- CYTOKINETICS, INCORPORATED payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-03-31 was $2.41M.
- CYTOKINETICS, INCORPORATED payment for debt extinguishment or debt prepayment cost for fiscal 2024 was $0.00.
- CYTOKINETICS, INCORPORATED payment for debt extinguishment or debt prepayment cost for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CYTOKINETICS, INCORPORATED payment for debt extinguishment or debt prepayment cost for fiscal 2022 was $2.41M.
- CYTOKINETICS, INCORPORATED payment for debt extinguishment or debt prepayment cost for fiscal 2021 was $0.00.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $2.41M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $2.41M 10-Q · filed 2023-11-03 | $2.41M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.41M 10-Q · filed 2023-08-03 | $2.41M derived: sum of 3 quarters · filed 2023-08-03 | $2.41M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $2.41M 10-Q · filed 2023-05-05 | $2.41M derived: sum of 2 quarters · filed 2023-05-05 | $2.41M derived: sum of 3 quarters · filed 2023-05-05 | $2.41M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $0.00 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $0.00 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |